Suzanne Lentzsch, MD
Enriched profileProfessor of Medicine; Director, Multiple Myeloma and Amyloidosis Program/Service · Columbia University Irving Medical Center
Suzanne Lentzsch is Professor of Medicine; Director, Multiple Myeloma and Amyloidosis Program/Service at Columbia University Irving Medical Center. OpenAlex indexes 512 publications with 18,147 citations (h-index 59); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 1 Sept 2026
Suzanne Lentzsch, MD, is Professor of Medicine at Columbia University Irving Medical Center / NewYork-Presbyterian Hospital. The public record shows 512 publications with 18,147 citations (h-index 59), centered on Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Protein Degradation and Inhibitors. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 16 companies, 4 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Multiple Myeloma Research and Treatments
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 171.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Sponsor: Tufts Medical Center
- Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Sponsor: Suzanne Lentzsch, MD
- Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Sponsor: Columbia University
Industry payments
Updated 1 Sept 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20258 payments$15,823openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20253 payments$12,375openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$10,539openpaymentsdata.cms.gov ↗
NIH funding
Updated 1 Sept 2026
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- CUIMC Calabresi Clinical Oncology Career Development Program
Columbia University Health Sciences
FY2026$895,145K12CA279872 - CUIMC Calabresi Clinical Oncology Career Development Program
Columbia University Health Sciences
FY2025$573,987K12CA279872 - Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma
Columbia University Health Sciences
FY2025$478,447R01CA252756
Congress activity
Updated 1 Sept 2026
118 congress contributions (2005–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
ASCO Annual Meeting
ASCO2026Co-author - Proteinuria with preserved renal function (PPRF): A retrospective cohort study in newly diagnosed multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Journal of clinical oncology
Clinical Trial2026 - Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Blood cancer journal
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04IMWG consensus on risk stratification in multiple myelomaArticle601 citations2013
- 05
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/suzanne-lentzsch-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Suzanne-Lentzsch-3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/SLentzsch
Mentions by others
where others cite or feature them- Other
bloodcancerunited.org/resources/blog/champions-myeloma-research-part-2-conversation-suzanne-lentzsch-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗ - Other
myelomasociety.org/officers/suzanne-lentzsch-md-phd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Humboldt University of Berlin (Charité), Germany
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - PhD
Humboldt University of Berlin, Germany
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - Board certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Co-Chair
NCI Myeloma Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗ - Board Member
International Myeloma Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Co-Chair
Career Development Committee, International Myeloma Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Scientific Advisory Board
Nexcella, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nexcella.com ↗ - Scientific Advisory Board
Immix Biopharma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Media & interviews
press, podcasts and appearances- Champions in Myeloma Research
Part 2: A Conversation with Suzanne Lentzsch, M.D., Ph.D. (interview with LLS/Blood Cancer United Chief Medical Officer Gwen Nichols)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myeloma.org ↗
- New Insights for Amyloidosis in Myeloma -- Suzanne Lentzsch
MD, #ASH24 (YouTube video interview)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Fahn, MD
Columbia University Irving Medical Center
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center